Cabaletta Bio is trading 6.38% higher at $1.50 in pre-market, but the reason for the rise remains unclear.
- Available search results showed no company-specific announcement explaining the October 19 move; the latest official press-release listing is dated October 5.
- Biotech shares were under pressure, with XBI reported down 3.65%, which does not explain Cabaletta Bio’s gain.